LONN.SW
A recent post claims the firm built a small cGMP cell therapy manufacturing facility and suggests vertical integration of manufacturing is a strategic priority for cell therapies. We view implications for third-party CDMOs as mixed and see greater direct benefit accruing to bioprocess tools and consumables providers.
Recent proof-backed thesis calls
One public call argues the company has built a small cGMP cell therapy manufacturing facility and frames in-house GMP capability as a potential strategic advantage for cell therapy programs. The original post is cited at https://x.com/artirkel (confidence 0.36).
Post claims a company has built a small cGMP cell therapy manufacturing facility and argues vertical integration of manufacturing is key for cell therapies; implies confidence/competence in GMP execution and potential strategic advantage for in-house manufacturing in cell therapy.
Current stance
Current recommendation: sell. Rationale: the vertical-integration trend in cell therapy tends to favor suppliers of bioprocess tools and consumables more than CDMOs; if customers internalize manufacturing, CDMO-like exposures face risk, likely gradual.
- risk via Cell therapy vertical integration trend benefits bioprocess tools/consumables more than CDMOs. from https://x.com/artirkel (confidence 0.36)
Top authors on this asset
Active and historical ticker theses
Active play 2033 notes the same risk: cell therapy vertical integration benefits bioprocess tools/consumables more than CDMOs and any negative impact on CDMOs would likely be gradual as customers internalize manufacturing.
Unlock full asset monitoring
Monitor company disclosures for verification of the claimed cGMP facility, regulatory filings, and sales/partnership announcements. Track indicators for demand shifts toward in-house manufacturing versus third-party CDMOs and for procurement trends in bioprocess tools and consumables.